Cologuard CRC screening test determined to be most cost-effective test for the medically underserved Alaska Native population

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study, published in Mayo Clinic Proceedings, demonstrates that Cologuard (mt-sDNA) is the most cost-effective colorectal cancer screening option in the Alaska Native population, as compared to colonoscopy and the fecal immunochemical test, for a wide range of adherence scenarios. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

When Olufunmilayo I. “Funmi” Olopade was born, the most common Nigerian career aspirations were pastor or teacher. Olopade’s father, a pastor, thought differently. He wanted his children to be scientists, economists, and doctors. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login